donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NTRA Natera > Detailed Quotes

NTRA Natera

41.380
+2.530+6.51%
Close 06/24 16:00 ET
41.38000.00%
Post Mkt Price 06/24 16:36 ET
High
41.800
Open
39.280
Turnover
66.66M
Low
38.210
Pre Close
38.850
Volume
1.65M
Market Cap
3.99B
P/E(TTM)
Loss
52wk High
129.090
Shares
96.31M
P/E(Static)
Loss
52wk Low
26.100
Float Cap
3.81B
Bid/Ask %
0.00%
Historical High
129.090
Shs Float
92.04M
Volume Ratio
1.13
Historical Low
6.520
Dividend TTM
--
Div Yield TTM
400
P/B
7.35
Dividend LFY
--
Div Yield LFY
966.65%
Turnover Ratio
1.79%
Amplitude
9.24%
Avg Price
40.523
Lot Size
1
Float Cap
3.81B
Bid/Ask %
0.00%
Historical High
129.090
Shs Float
92.04M
Volume Ratio
1.13
Historical Low
6.520
Dividend TTM
--
P/B
7.35
Dividend LFY
--
Turnover Ratio
1.79%
Amplitude
9.24%
Avg Price
40.523
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual’s tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...